ADReCS

Pharmaceutical Information

Drug Name	Cabergoline
Drug ID	BADD_D00329
Description	Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
Indications and Usage	For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.
Marketing Status	approved
ATC Code	G02CB03; N04BC06
DrugBank ID	DB00248
KEGG ID	D00987
MeSH ID	D000077465
PubChem ID	54746
TTD Drug ID	D04EGX
NDC Product Code	40016-011; 59762-1005; 47848-009; 14096-153; 23155-823; 70512-860; 50090-5834; 0093-5420; 50742-118
UNII	LL60K9J05T
Synonyms	Cabergoline \| 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea \| FCE 21336 \| FCE-21336 \| Cabaser \| Cabaseril \| Dostinex \| Galastop \| Cabergoline Diphosphate \| 1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate

Chemical Information

Molecular Formula	C26H37N5O2
CAS Registry Number	81409-90-7
SMILES	CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Mitral valve disease	02.07.01.003	0.004804%
Drug intolerance	08.06.01.013	0.024022%		Not Available
Psychotic disorder	19.03.01.002	0.012011%
Congenital genitourinary abnormality	21.15.02.002; 20.08.03.001; 03.06.02.002	-	-	Not Available
Autism spectrum disorder	17.03.05.003; 19.22.02.002	0.007207%		Not Available
Pulmonary arterial hypertension	24.08.03.003; 22.06.01.002	0.009609%		Not Available
Hypersexuality	19.08.03.005	0.024022%		Not Available
Treatment failure	08.06.01.017	0.007207%		Not Available
Regurgitation	07.01.07.004	-	-	Not Available
Low birth weight baby	18.04.02.003	0.007207%		Not Available
Type 2 diabetes mellitus	14.06.01.003; 05.06.01.003	0.007207%		Not Available
Compulsive shopping	19.06.05.004	0.014413%		Not Available
Foetal growth restriction	18.03.01.002	0.007207%
Posterior reversible encephalopathy syndrome	17.13.02.007	0.009609%
Substance-induced psychotic disorder	19.03.01.007; 12.03.01.053	0.007207%		Not Available
Reversible cerebral vasoconstriction syndrome	24.04.06.026; 17.08.02.014; 18.06.01.004	0.024022%		Not Available
Gambling disorder	19.07.06.015	0.019218%		Not Available
Empty sella syndrome	05.03.04.009	0.026424%		Not Available
Hemianopia heteronymous	17.17.01.023; 06.02.07.006	0.012011%		Not Available
Jealous delusion	19.10.01.006	0.009609%		Not Available
Normal newborn	18.08.06.001	0.004804%		Not Available
Prolactin-producing pituitary tumour	16.24.07.001; 05.03.05.005	0.004804%		Not Available
Speech disorder developmental	19.19.01.003; 17.02.08.011	0.004804%		Not Available
Carotid aneurysm rupture	24.02.04.002; 17.08.01.044	0.014413%		Not Available
Neuroendocrine tumour	16.24.01.009; 05.08.01.013	0.004804%		Not Available
Pituitary tumour recurrent	05.03.05.004; 16.24.01.010	0.004804%		Not Available
Spinal pain	17.10.01.020; 15.02.01.008; 08.01.08.030	0.007207%		Not Available
Ophthalmic vein thrombosis	24.01.05.011; 06.07.02.007	0.009609%		Not Available
Cardiac valve sclerosis	02.07.02.011	0.004804%		Not Available
Chiasma syndrome	17.17.01.028; 16.32.03.036; 06.02.08.005	0.004804%		Not Available

The 9th Page First Pre 9 10 Next Last Total 10 Pages